DevinTCorrigan Profile Banner
Devin T. Corrigan Profile
Devin T. Corrigan

@DevinTCorrigan

Followers
24
Following
22
Media
2
Statuses
24

PhD candidate in the Zang lab studying novel immune checkpoints and making immunotherapies • NYC • CAR-T cells • Antibodies • Cancer

New York, NY
Joined February 2021
Don't wanna be here? Send us removal request.
@IFI_Einstein
Katz Institute for Immunotherapy
1 year
Join us for the IFI-Joint Lab Meeting featuring presentations; @DevinTCorrigan from @xingxing_zang Lab and Divya Kenchappa from Saenger’s Lab!! Exciting Insights on Cancer Immunotherapy & Immune Cell Regulations!! @EinsteinPhD @EinsteinMSTP @EinsteinMed @MontefioreNYC
0
4
6
@NextPointTX
NextPoint Therapeutics
1 year
Exciting Preclinical Data on Our Novel B7-H7 T Cell Engager Announced at #SITC2024! This innovative approach shows promise in overcoming the tumor microenvironment challenges. Can't join us in Houston? Explore the details here: https://t.co/KGQYxIE27D
0
1
1
@DevinTCorrigan
Devin T. Corrigan
1 year
Last week I was honored to receive the Barry R. Bloom speaker award for the top Work-in-Progress presentation in the Microbiology and Immunology department. Thank you to my mentor @xingxing_zang for all of your support and guidance! @EinsteinMed @EinsteinPhD
2
1
10
@EinsteinMed
Albert Einstein College of Medicine - Official
1 year
Immunotherapy has revolutionized cancer care. Now @theNCI-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) has announced the new Marilyn and Stanley M. Katz Institute for Immunotherapy for Cancer and Inflammatory Disorders. More at https://t.co/UCodavRcxW. 1/2
1
5
9
@xingxing_zang
XingXing Zang
1 year
Nice annual scientific retreat of Montefiore Einstein Comprehensive Cancer Center at the beautiful Glen Island Harbour Club.
0
6
17
@xingxing_zang
XingXing Zang
1 year
Posters of four important and exciting research projects that are led by our lab members Marc Pulanco @MC_Pulanco, Ankit Tanwar @DrAnkitTanwar1, Devin Corrigan @DevinTCorrigan, Zidong (Andy) Li @AndyLi81701371.
@xingxing_zang
XingXing Zang
1 year
Nice annual scientific retreat of Montefiore Einstein Comprehensive Cancer Center at the beautiful Glen Island Harbour Club.
0
7
23
@xingxing_zang
XingXing Zang
1 year
As our lab tradition, the whole lab out for lunch to celebrate first birthday of a new lab member @XiaonaSun143635 @MC_Pulanco @DevinTCorrigan @DrAnkitTanwar1 @Miazhang0116 @Yunchao_Shentu @AndyLi81701371 @YulinWang95752 @MissYolandaLiu
0
9
14
@EinsteinMed
Albert Einstein College of Medicine - Official
1 year
Researchers at @theNCI-designated Montefiore Einstein Comprehensive Cancer Center have shown a breakthrough therapy for treating blood cancers can be adapted to treat solid #tumors—an advance that could transform cancer treatment. https://t.co/kqOD82LQEE #CancerResearch #MECCC
1
7
13
@xingxing_zang
XingXing Zang
1 year
I’m thrilled our paper on new CAR treating human solid cancers is out in @ScienceAdvances today. Huge credit to stellar student @einstein_mstp Christopher Nishimura, great collaborators Deyou Zheng @zhengdy and @UTSWMedCenter Cheng Cheng Zhang https://t.co/KHfK6SsO1T
Tweet card summary image
science.org
A TMIGD2 costimulatory domain in B7-H3 CAR-T cells imparts advantageous metabolic, memory, exhaustion, and CD8/CD4 phenotypes.
3
9
31
@xingxing_zang
XingXing Zang
2 years
My thoughts on Chimeric Antigen Receptor (CAR) immune-cell therapy. The next frontier for CAR therapy is solid cancers and autoimmune diseases, also holds promises for aging, Alzheimer’s disease, etc. The Next Chapter of Science | Technology Networks
technologynetworks.com
Join us as we explore how innovation, ethics and even aesthetics look set to influence the landscape of life science research, creating new possibilities for treating human diseases, feeding our...
0
3
8
@xingxing_zang
XingXing Zang
2 years
Grateful Oscar Ortiz from SebastianStrong Foundation came to my office and present a check for our CAR research. My lab, David Loeb and Allison Martin are developing next-generation CAR-T therapy treating human pediatric Rhabdomyosarcoma. @EinsteinMed @MontefioreNYC
2
3
23
@xingxing_zang
XingXing Zang
2 years
Great congratulations to NextPoint!!!  It took 10 years moving from our original discovery of HHLA2 as a new B7 immune checkpoint in 2013 to NextPoint’s soon clinical trials in cancer patients. @EinsteinMed @MontefioreNYC
@NextPointTX
NextPoint Therapeutics
2 years
We received FDA acceptance of our investigational new drug (IND) application to advance NPX887, a monoclonal antibody targeting HHLA2 that is designed to enhance immune responses in the tumor microenvironment. Read more at https://t.co/g2vxqa9EbB.
3
3
10
@EinsteinMed
Albert Einstein College of Medicine - Official
2 years
Dr. @Xingxing_Zang develops immune-checkpoint inhibitors (ICIs)—monoclonal antibodies that use the immune system to fight cancer cells. Two of his compounds are in clinical trials. He sees ICIs as the future of #LungCancertreatment. https://t.co/vFpsE31pBg
0
2
15
@xingxing_zang
XingXing Zang
2 years
Thrilled to share a new paper on @Dev_Cell from a fruitful collaboration between @WenjunGuoLab and my lab, showing the Sox9-B7x pathway in @breastcancer immune evasion and a potential new @immunotherapy. @EinsteinCellBio @EinsteinMed @MontefioreNYC
@Dev_Cell
Developmental Cell
2 years
Online now: A SOX9-B7x axis safeguards dedifferentiated tumor cells from immune surveillance to drive breast cancer progression
6
10
37
@DevinTCorrigan
Devin T. Corrigan
2 years
Excited to have received the William R. Jacobs Jr. Award from the Microbiology and Immunology Department at @EinsteinMed. Thank you to my mentor @xingxing_zang for your continued support! @EinsteinPhD
4
1
14
@NCIARTNet
Acquired Resistance to Therapy Network (ARTNet)
2 years
The journey to bring research from the bench to bedside is long but exciting and achievable as shown by @NCIARTNet PI @xingxing_zang @EinsteinMed during his presentation at the NCIARTNet scientific meeting today
1
5
7
@EinsteinMed
Albert Einstein College of Medicine - Official
3 years
In a paper published online today in @jclinicalinvest, an Einstein research team led by Xingxing Zang, https://t.co/d0sPlsGnnn., Ph.D., describes its findings that could bolster the effectiveness of immune-checkpoint therapy. Learn more at: https://t.co/KqFC585MMO #cancer
0
4
12
@infdisease_news
Immunology of Infectious Disease News
4 years
Elise Ishida & @EinsteinMed researchers generated human IgG monoclonal antibodies to AM/LAM from B cells of two asymptomatic individuals exposed to or latently infected with M. #tuberculosis. https://t.co/Uh5VK0GcV1
1
3
4
@TrendsMicrobiol
Trends in Microbiology
3 years
Out online now: Opinion piece on "Monoclonal antibodies to lipoarabinomannan/arabinomannan – characteristics and implications for tuberculosis research and diagnostics" @EinsteinMed @Lowarylab @CSU_MIP https://t.co/NQBQT3AsKs
0
1
2